MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.amjcard.2018.02.022

Медицинская библиотека · The American journal of cardiology · 2018

Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea.

Costanzo Maria Rosa, Ponikowski Piotr, Javaheri Shahrokh, Augostini Ralph, Goldberg Lee R, Holcomb Richard, Kao Andrew, Khayat Rami N, Oldenburg Olaf, Stellbrink Christoph, Abraham William T, remedē System Pivotal Trial Study Group

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Transvenous phrenic nerve stimulation improved sleep metrics and quality of life after 6 months versus control in the remedē System Pivotal Trial. This analysis explored the effectiveness of phrenic nerve stimulation in patients with central sleep apnea after 12 months of therapy. Reproducibility of treatment effect was assessed in the former control group in whom the implanted device was initially inactive for the sixth month and subsequently activated when the randomized control assessments were complete. Patients with moderate-to-severe central sleep apnea implanted with the remedē System were randomized to therapy activation at 1 month (treatment) or after 6 months (control). Sleep indices were assessed from baseline to 12 months in the treatment group and from 6 to 12 months in former controls. In the treatment group, a ≥50% reduction in apnea-hypopnea index occurred in 60% of patients at 6 months (95% confidence interval [CI] 47% to 64%) and 67% (95% CI 53% to 78%) at 12 months. After 6 months of therapy, 55% of former controls (95% CI 43% to 67%) achieved ≥50%reduction in apnea-hypopnea index. Patient Global Assessment was markedly ormoderately improved at 6 and 12 months in 60% of treatment patients.Improvements persisted at 12 months. A serious adverse event within 12 months occurred in 13 patients (9%). Phrenic nerve stimulation produced sustained improvements in sleep indices and quality of life to at least 12 months in patients with central sleep apnea. The similar improvement of former controls after 6 months of active therapy confirms benefits are reproducible and reliable.

Для цитирования: Costanzo Maria Rosa, Ponikowski Piotr, Javaheri Shahrokh, Augostini Ralph, Goldberg Lee R, Holcomb Richard, Kao Andrew, Khayat Rami N, Oldenburg Olaf, Stellbrink Christoph, Abraham William T, remedē System Pivotal Trial Study Group. Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea.. The American journal of cardiology. 2018. DOI: 10.1016/j.amjcard.2018.02.022.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.